Vicus Capital increased its position in Bristol-Myers Squibb Company (NYSE:BMY) by 1.7% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 6,192 shares of the biopharmaceutical company’s stock after buying an additional 106 shares during the period. Vicus Capital’s holdings in Bristol-Myers Squibb were worth $345,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of BMY. Northstar Group Inc. boosted its position in shares of Bristol-Myers Squibb by 35.9% in the first quarter. Northstar Group Inc. now owns 5,491 shares of the biopharmaceutical company’s stock worth $298,000 after buying an additional 1,450 shares in the last quarter. New England Research & Management Inc. boosted its position in shares of Bristol-Myers Squibb by 8.8% in the first quarter. New England Research & Management Inc. now owns 28,317 shares of the biopharmaceutical company’s stock worth $1,540,000 after buying an additional 2,300 shares in the last quarter. Raymond James Trust N.A. boosted its position in shares of Bristol-Myers Squibb by 2.9% in the first quarter. Raymond James Trust N.A. now owns 126,251 shares of the biopharmaceutical company’s stock worth $6,865,000 after buying an additional 3,543 shares in the last quarter. S&CO Inc. boosted its position in shares of Bristol-Myers Squibb by 0.8% in the first quarter. S&CO Inc. now owns 384,866 shares of the biopharmaceutical company’s stock worth $20,929,000 after buying an additional 3,116 shares in the last quarter. Finally, Douglass Winthrop Advisors LLC boosted its position in shares of Bristol-Myers Squibb by 44.0% in the first quarter. Douglass Winthrop Advisors LLC now owns 48,109 shares of the biopharmaceutical company’s stock worth $2,616,000 after buying an additional 14,700 shares in the last quarter. Institutional investors own 69.68% of the company’s stock.

Shares of Bristol-Myers Squibb Company (NYSE BMY) traded up 0.35% during mid-day trading on Wednesday, reaching $57.87. The company’s stock had a trading volume of 2,069,885 shares. The stock has a market capitalization of $94.90 billion, a P/E ratio of 21.14 and a beta of 1.17. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $60.45. The company has a 50 day moving average price of $55.97 and a 200 day moving average price of $55.09.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the business earned $0.69 EPS. Bristol-Myers Squibb’s quarterly revenue was up 5.6% on a year-over-year basis. On average, equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 7th were paid a $0.39 dividend. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.71%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 56.73%.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/23/vicus-capital-buys-106-shares-of-bristol-myers-squibb-company-bmy.html.

A number of research analysts have commented on BMY shares. Robert W. Baird started coverage on Bristol-Myers Squibb in a research note on Tuesday, April 25th. They set an “outperform” rating on the stock. BMO Capital Markets cut Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price objective on the stock. in a research note on Wednesday, May 3rd. Jefferies Group LLC restated a “buy” rating and set a $64.00 price objective on shares of Bristol-Myers Squibb in a research note on Monday, June 5th. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price objective on the stock in a research note on Monday, June 5th. Finally, BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company. Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $62.13.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 6,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the transaction, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.23% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.